Article in Journal of thrombosis and haemostasis : JTH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 7 institutions in 2 countries.
Laura B HarringtonKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Alexa N EhlertDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Evan L ThackerDepartment of Public Health, Brigham Young University, Provo, UT, USA.
Nancy S JennyDepartment of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine, Colchester, VT, USA.
Oscar LopezDepartment of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
Mary CushmanDepartment of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine, Colchester, VT, USA.ORCID 0000-0002-7871-6143
Annette FitzpatrickDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
Kenneth J MukamalDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Majken K JensenDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Harvard University · USUniversity of Vermont · USBeth Israel Deaconess Medical Center · USBrigham Young University · USUniversity of Copenhagen · DKUniversity of Pittsburgh · USUniversity of Washington · US
Funding
Exceptional Survival: Trajectories to Functional Aging (CHS All Stars)R01AG023629 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEWMAN, ANNE B. · 2004 to 2016
$9.5M
CVD Epidemiology Training Program in Behavior, the Environment and Global HealthT32HL098048 · NHLBI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Goodarz Danaei, ERIC B RIMM · 2009 to 2026
$6.9M
CHS research resources for the cardiovascular health of older adultsU01HL130114 · NHLBI · UNIVERSITY OF WASHINGTON · PI BURKE, GREGORY L, KRONMAL, RICHARD A · 2016 to 2019
$6.6M
CHS Events Follow-up StudyU01HL080295 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M · 2005 to 2008
$4.6M
Predictors of Alheimers Disease in Mild Cognitive ImpairmentR01AG020098 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LOPEZ, OSCAR L. · 2002 to 2011
$3.7M
Novel lipoprotein particles, brain abnormalities, and risk of dementia and strokeR01NS089638 · NINDS · HARVARD SCHOOL OF PUBLIC HEALTH · PI JENSEN, MAJKEN KAROLINE · 2015 to 2018
$2.6M
Role of EIIIA fibronectin in pulmonary fibrosisR01HL085083 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WHITE, ERIC S · 2007 to 2011
$1.9M
Physical Activity, Sedentary Behavior, and Venous Thromboembolism RiskK01HL139997 · NHLBI · KAISER FOUNDATION RESEARCH INSTITUTE · PI HARRINGTON, LAURA BRIENNE · 2018 to 2022
$942k
INFLAMMATION MARKERS OVER TIME IN CARDIOVASCULAR DISEASER01HL046696 · NHLBI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI TRACY, RUSSELL P · 1992 to 2002
$595k
CENTRAL BLOOD ANALYSIS LABORATORY FOR CHSN01HC085086 · HC · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI TRACY, RUSSELL P · 1988 to 2000
–
CORONARY HEART DISEASE &STROKE IN PEOPLE AGED 65-84N01HC085083 · HC · UNIVERSITY OF CALIFORNIA DAVIS · PI ROBBINS, JOHN A · 1988 to 1999
–
CORONARY HEART DISEASE AND STROKE IN PEOPLE AGED 65-84N01HC085082 · HC · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KULLER, LEWIS H · 1988 to 2000
backgroundHemostasis is a key factor in cerebrovascular disease, but the association of hemostatic factors with cognitive decline is unclear.
objectiveTo prospectively evaluate associations of 20 hemostatic factor levels with changes in cognition during ≥8 years of follow-up in the Cardiovascular Health Study (CHS) of older adults.
methodsWe included participants of an existing CHS cross-sectional substudy (n = 400) with hemostatic factors measured in 1989-1990. Between 1989-1990 and 1998-1999, cognitive function was measured using the Modified Mini-Mental State Examination (3MSE) and Digit Symbol Substitution Tests. Mixed-effects linear regression models estimated change in cognitive function over time, adjusting for sociodemographic and clinical factors and APOE genotype, using Bonferroni adjustment. We also derived principal components to account for the interrelationship among factors.
resultsOf 20 factors evaluated individually, only higher levels of plasmin-α
conclusionsLevels of PAP, TPFI, and FXc and a combination of factors driven by PAP, D-dimer, and F1.2 were associated with cognitive decline. Whether these findings can be used to improve dementia prevention or prediction requires further study.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Hemostatic factor levels and cognitive decline in older adults: The Cardiovascular Health Study. · full record | OpenQuestion